Physician profile
Sandra Kang
NPI 1679005870
$2,541.87
in general payments reported to CMS, 2019-2025
38 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $794 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,497 · Education: $45.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,496.81 |
| Education | $45.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $250.05 | 2024-2025 | Lynparza, Enhertu, Tagrisso |
| Pfizer INC. | $227.90 | 2024-2025 | |
| Janssen Biotech, INC. | $201.63 | 2024-2025 | Darzalex, Talvey, Rybrevant |
| Merck Sharp & Dohme LLC | $186.88 | 2024-2025 | Keytruda, Welireg |
| Novartis Pharmaceuticals Corporation | $184.40 | 2024-2025 | |
| Astellas Pharma US INC | $116.47 | 2024-2025 | Padcev, Xtandi, Vyloy |
| Abbvie INC. | $97.08 | 2024-2025 | |
| Incyte Corporation | $91.92 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Stemline Therapeutics INC. | $76.25 | 2025 | Orserdu |
| Daiichi Sankyo INC. | $74.69 | 2024-2025 | Datroway, Enhertu |
| Eisai INC. | $72.59 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.48 | 2024-2025 | |
| Genentech USA, INC. | $69.61 | 2024-2025 | Venclexta, Tecentriq, Itovebi |
| Jazz Pharmaceuticals INC. | $66.41 | 2025 | |
| Genzyme Corporation | $66.35 | 2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $51.28 | 2025 | Tevimbra, Brukinsa |
| Glaxosmithkline, LLC. | $49.43 | 2025 | Ojjaara |
| Array Biopharma INC | $47.55 | 2025 | Braftovi, Mektovi, Tukysa |
| Gilead Sciences, INC. | $42.28 | 2024-2025 | Trodelvy |
| Adc Therapeutics America, INC. | $37.72 | 2024-2025 | |
| Sobi, INC | $35.70 | 2025 | |
| Tersera Therapeutics LLC | $34.55 | 2024 | Zoladex |
| Sun Pharmaceutical Industries INC. | $32.70 | 2025 | |
| Tempus Ai, INC | $28.02 | 2025 | Xt Cdx |
| Alexion Pharmaceuticals, INC. | $27.63 | 2024 | Ultomiris |
| Mirati Therapeutics, INC. | $27.21 | 2024 | Krazati |
| Celgene Corporation | $26.98 | 2024 | Reblozyl |
| Adaptive Biotechnologies Corporation | $26.84 | 2025 | Clonoseq |
| Alnylam Pharmaceuticals INC. | $26.81 | 2025 | Givlaari |
| Kite Pharma, INC. | $25.02 | 2025 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $24.07 | 2024 | Onivyde |
| Exelixis INC. | $22.57 | 2024 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $22.36 | 2025 | Qinlock, Tgct |
| Legend Biotech USA INC. | $21.93 | 2025 | Carvykti |
| Caris Mpi, INC. | $21.55 | 2025 | Mi Cancer Seek |
| Coherus Oncology, INC. | $20.01 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.79 | 2025 | Erleada |
| Teva Pharmaceuticals USA, INC. | $16.16 | 2024 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.